Analyzing Basel Medical Group (NASDAQ:BMGL) & Organon & Co. (NYSE:OGN)

Basel Medical Group (NASDAQ:BMGL) and Organon & Co. (NYSE:OGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Volatility & Risk

Basel Medical Group has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Profitability

This table compares Basel Medical Group and Organon & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Organon & Co.	3.01%	122.01%	6.74%

Institutional & Insider Ownership

77.4% of Organon & Co. shares are held by institutional investors. 2.0% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Basel Medical Group and Organon & Co., as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1	0	0	0	1.00
Organon & Co.	5	1	0	1	1.57

Organon & Co. has a consensus target price of $8.50, suggesting a potential upside of 38.32%. Given Organon & Co.’s stronger consensus rating and higher possible upside, analysts clearly believe Organon & Co. is more favorable than Basel Medical Group.

Earnings and Valuation

This table compares Basel Medical Group and Organon & Co.”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90 million	1.30	-$9.50 million	N/A	N/A
Organon & Co.	$6.22 billion	0.26	$187.00 million	$0.71	8.65

Organon & Co. has higher revenue and earnings than Basel Medical Group.

Summary

Organon & Co. beats Basel Medical Group on 11 of the 12 factors compared between the two stocks.

About Basel Medical Group

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.